Population pharmacokinetics of racemic warfarin in adult patients

1985 ◽  
Vol 13 (3) ◽  
pp. 213-227 ◽  
Author(s):  
D. R. Mungall ◽  
T. M. Ludden ◽  
J. Marshall ◽  
D. W. Hawkins ◽  
R. L. Talbert ◽  
...  
Keyword(s):  
Population Pharmacokinetics ◽  
Adult Patients ◽  
Racemic Warfarin

Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?

2019 ◽  
Vol 75 (9) ◽  
pp. 1219-1226 ◽  
Author(s):  
A. J. Heffernan ◽  
A. Germano ◽  
F. B. Sime ◽  
Jason A. Roberts ◽  
E. Kimura
Keyword(s):  
Septic Shock ◽  
Population Pharmacokinetics ◽  
Adult Patients ◽  
Dosing Regimens

scholarly journals Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy

2016 ◽  
Vol 83 (3) ◽  
pp. 498-509 ◽  
Author(s):  
Xiaoying Xu ◽  
Dmytro Khadzhynov ◽  
Harm Peters ◽  
Ricardo L. Chaves ◽  
Kamal Hamed ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Population Pharmacokinetics ◽  
Adult Patients

scholarly journals Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
Sílvia M. Illamola ◽  
Hoa Q. Huynh ◽  
Xiaoxi Liu ◽  
Zubin N. Bhakta ◽  
Catherine M. Sherwin ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Population Pharmacokinetics ◽  
Drug Disposition ◽  
Adult Patients ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Concentration Data ◽  
First Order ◽  
Dosing Regimens ◽  
Pulmonary Exacerbations

ABSTRACTPractitioners commonly use amikacin in patients with cystic fibrosis. Establishment of the pharmacokinetics of amikacin in adults with cystic fibrosis may increase the efficacy and safety of therapy. This study was aimed to establish the population pharmacokinetics of amikacin in adults with cystic fibrosis. We used serum concentration data obtained during routine therapeutic drug monitoring and explored the influence of patient covariates on drug disposition. We performed a retrospective chart review to collect the amikacin dosing regimens, serum amikacin concentrations, blood sampling times, and patient characteristics for adults with cystic fibrosis admitted for treatment of acute pulmonary exacerbations. Amikacin concentrations were retrospectively collected for 49 adults with cystic fibrosis, and 192 serum concentrations were available for analysis. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling with the first-order conditional estimation method. A two-compartment model with first-order elimination best described amikacin pharmacokinetics. Creatinine clearance and weight were identified as significant covariates for clearance and the volume of distribution, respectively, in the final model. Residual variability was modeled using a proportional error model. Typical estimates for clearance, central and peripheral volumes of distribution, and intercompartmental clearance were 3.06 liters/h, 14.4 liters, 17.1 liters, and 0.925 liters/h, respectively. The pharmacokinetics of amikacin in individuals with cystic fibrosis seems to differ from those in individuals without cystic fibrosis. However, further investigations are needed to confirm these results and, thus, the need for variations in amikacin dosing. Future pharmacodynamic studies will potentially establish the optimal amikacin dosing regimens for the treatment of acute pulmonary exacerbations in adult patients with CF.

Population pharmacokinetics study of dexmedetomidine in Chinese adult patients during spinal anesthesia

2016 ◽  
Vol 54 (03) ◽  
pp. 200-207 ◽  
Author(s):  
Yun Kuang ◽  
Yu-xia Xiang ◽  
Cheng-Xian Guo ◽  
Ran-ran Zhang ◽  
Guo-Ping Yang ◽  
...  
Keyword(s):  
Spinal Anesthesia ◽  
Population Pharmacokinetics ◽  
Adult Patients ◽  
Chinese Adult ◽  
Pharmacokinetics Study
Sign in / Sign up

Export Citation Format

Share Document